{
    "Trade/Device Name(s)": [
        "Direct LDL Cholesterol (LDL)"
    ],
    "Submitter Information": "Randox Laboratories Limited",
    "510(k) Number": "K161691",
    "Predicate Device Reference 510(k) Number(s)": [
        "K982529"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "MRR"
    ],
    "Summary Letter Date": "February 6, 2017",
    "Summary Letter Received Date": "February 9, 2017",
    "Submission Date": "March 16, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1475"
    ],
    "Regulation Name(s)": [
        "Lipoprotein test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "LDL cholesterol"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube"
    ],
    "Instrument(s)/Platform(s)": [
        "RX Daytona Plus"
    ],
    "Method(s)/Technology(ies)": [
        "Clearance method",
        "Enzyme assay"
    ],
    "Methodologies": [
        "Quantitative in vitro determination"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Randox Direct LDL Cholesterol (LDL) quantitative in vitro assay for human serum and plasma on the RX Daytona Plus platform",
    "Indications for Use Summary": "For quantitative in vitro determination of LDL-cholesterol concentration in human plasma and serum, aiding diagnosis and treatment of lipid disorders, atherosclerosis, and various liver and renal diseases.",
    "fda_folder": "Clinical Chemistry"
}